Hagop Kantarjian

Hagop Kantarjian

UNVERIFIED PROFILE

Are you Hagop Kantarjian?   Register this Author

Register author
Hagop Kantarjian

Hagop Kantarjian

Publications by authors named "Hagop Kantarjian"

Are you Hagop Kantarjian?   Register this Author

100Publications

481Reads

19Profile Views

The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.

Cancer 2020 Jul 13;126(14):3192-3201. Epub 2020 May 13.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32909DOI Listing
July 2020

Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.

Cancer 2020 Jul 22. Epub 2020 Jul 22.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.33094DOI Listing
July 2020

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.

Am J Hematol 2020 06 10;95(6):691-709. Epub 2020 Apr 10.

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25792DOI Listing
June 2020

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

Am J Hematol 2020 Jun 5. Epub 2020 Jun 5.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25896DOI Listing
June 2020

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.

J Hematol Oncol 2020 Jun 5;13(1):70. Epub 2020 Jun 5.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00905-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275444PMC
June 2020

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.

Cancer 2020 Mar 3;126(6):1152-1160. Epub 2019 Dec 3.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32606DOI Listing
March 2020

t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?

Ann Hematol 2020 Mar 31;99(3):487-500. Epub 2020 Jan 31.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0072, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-03909-7DOI Listing
March 2020

New drug approvals in oncology.

Nat Rev Clin Oncol 2020 03 4;17(3):140-146. Epub 2020 Feb 4.

Friends of Cancer Research, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0313-2DOI Listing
March 2020

Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.

Clin Lymphoma Myeloma Leuk 2020 Mar 20. Epub 2020 Mar 20.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.03.005DOI Listing
March 2020

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Am J Hematol 2020 02 29;95(2):227-229. Epub 2019 Aug 29.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25610DOI Listing
February 2020

CPX-351 (vyxeos) in AML.

Leuk Lymphoma 2020 02 24;61(2):288-297. Epub 2019 Sep 24.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1660970DOI Listing
February 2020

Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.

Br J Haematol 2020 01 30;188(2):207-223. Epub 2019 Sep 30.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16207DOI Listing
January 2020

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Leuk Lymphoma 2019 12 27;60(13):3292-3295. Epub 2019 Jun 27.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1633635DOI Listing
December 2019

Treatment-free remission in chronic myeloid leukemia.

Clin Adv Hematol Oncol 2019 Dec;17(12):686-696

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
December 2019

Recent advances in the treatment of acute lymphoblastic leukemia.

Leuk Lymphoma 2019 11 16;60(11):2606-2621. Epub 2019 May 16.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1605071DOI Listing
November 2019

Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?

Cancer 2019 11 10;125(21):3891-3892. Epub 2019 Jul 10.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32385DOI Listing
November 2019

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.

Am J Hematol 2019 10 28;94(10):E256-E259. Epub 2019 Jul 28.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25571DOI Listing
October 2019

The many roads to universal health care in the USA.

Lancet Oncol 2019 10 28;20(10):e601-e605. Epub 2019 Aug 28.

Rice University Baker Institute, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30517-0DOI Listing
October 2019

Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia.

Open Forum Infect Dis 2019 Oct 28;6(10):ofz357. Epub 2019 Sep 28.

Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofz357DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765346PMC
October 2019

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Lancet Haematol 2019 Aug 14;6(8):e398-e408. Epub 2019 Jun 14.

Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30087-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658341PMC
August 2019

SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Clin Lymphoma Myeloma Leuk 2019 08 3;19(8):471-479. Epub 2019 Jul 3.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.06.011DOI Listing
August 2019

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.

Clin Epigenetics 2019 07 22;11(1):106. Epub 2019 Jul 22.

Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-019-0704-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647096PMC
July 2019

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Cancer Cell 2019 05 2;35(5):721-737.e9. Epub 2019 May 2.

The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center; Department of Leukemia, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.03.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620028PMC
May 2019

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

N Engl J Med 2019 05;380(22):2095-2103

From the Departments of Leukemia (N.J., M. Keating, P.T., A.F., J.B., G.B., K.T., Z.E., T.K., M. Konopleva, Y.A., M.Y., C.D., P.B., M.O., N.P., E.J., K. Sasaki, K. Sondermann, N.C., C.W., A.A., H.K., W.W.), Lymphoma and Myeloma (N.F.), Hematopathology (R.K.-S., K.P., J.J.), Diagnostic Radiology (N.G.), Biostatistics (X.W.), and Experimental Therapeutics (W.P., V.G.), University of Texas M.D. Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1900574DOI Listing
May 2019

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.

Clin Adv Hematol Oncol 2019 May;17(5):268-270

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
May 2019

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Ther Adv Hematol 2019 19;10:2040620719849496. Epub 2019 May 19.

Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719849496DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535741PMC
May 2019

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

N Engl J Med 2019 04;380(17):1628-1637

From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815105DOI Listing
April 2019

Treatment of relapsed/refractory acute lymphoblastic leukemia.

Clin Adv Hematol Oncol 2019 Mar;17(3):166-175

University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
March 2019